Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company operating in the biotechnology and pharmaceutical research industries, with a strategic focus on developing oncology therapeutics. The company is publicly traded on the Nasdaq under the ticker CRBP and concentrates on discovering and advancing differentiated drug candidates designed to address serious diseases with high unmet medical need, particularly in cancer.
Historically, Corbus focused on inflammatory and fibrotic diseases through cannabinoid receptor type 2 (CB2) agonists, most notably lenabasum. Following multiple late-stage clinical setbacks, the company undertook a strategic transformation beginning in 2022–2023, pivoting its pipeline and corporate strategy toward oncology. This evolution included divesting or deprioritizing its earlier immunology programs and reallocating capital toward cancer-focused assets, marking a fundamental repositioning of the company’s long-term business model.
Business Operations
Corbus conducts its operations primarily through its wholly owned subsidiary, Corbus Pharmaceuticals, Inc., which manages research, development, and corporate functions. The company does not generate product revenue and operates as a development-stage enterprise, funding activities through equity financings and strategic transactions. Its core business activities are centered on preclinical and clinical development, regulatory strategy, and portfolio management rather than commercial manufacturing or sales.
The company’s current operations are focused on its oncology pipeline, led by CRB-701, an antibody-drug conjugate (ADC) targeting Nectin-4, a protein commonly expressed in several solid tumors. Corbus controls development and global rights outside of certain territories through licensing arrangements. The company relies extensively on third-party contract research organizations and manufacturing partners for clinical trials, drug production, and specialized development services, which is typical for biopharmaceutical companies at this stage.
Strategic Position & Investments
Corbus’s strategic direction is centered on building a focused oncology portfolio, with an emphasis on antibody-drug conjugate technology as a differentiated therapeutic approach. The acquisition and advancement of CRB-701 represents a cornerstone investment and reflects management’s intent to concentrate resources on assets with clearer clinical and commercial pathways in oncology.
The company has pursued growth primarily through licensing transactions rather than acquisitions of operating companies, allowing it to gain access to novel technologies while maintaining a lean organizational structure. Corbus continues to evaluate additional oncology assets and platform opportunities that align with its capital constraints and development expertise. Its strategy emphasizes disciplined capital allocation, milestone-driven development, and creating optionality for future partnerships or out-licensing arrangements.
Geographic Footprint
Corbus Pharmaceuticals is headquartered in the United States, with its principal executive offices located in Massachusetts. The company’s operational footprint is primarily domestic, encompassing corporate management, clinical oversight, and regulatory activities within the U.S. market.
Internationally, Corbus’s presence is indirect and largely driven by clinical development activities and licensing arrangements. Clinical trials and manufacturing services may involve partners in Europe and Asia, depending on program requirements. While the company does not maintain significant physical offices outside the U.S., its development programs are designed with global regulatory pathways in mind, reflecting an intent to address international oncology markets over time.
Leadership & Governance
Corbus is led by an executive team with experience in oncology drug development, capital markets, and corporate strategy. Leadership has played a central role in executing the company’s strategic pivot from immunology to oncology, reshaping the pipeline and organizational focus in response to prior clinical outcomes.
Key executives disclosed in public filings include:
- Yuval Cohen – Chief Executive Officer
- John McGuire – Chief Financial Officer
- Pablo Cagnoni, M.D. – President and Chief Medical Officer
The leadership team emphasizes a strategy centered on scientific rigor, portfolio focus, and value creation through targeted oncology innovation. Governance is overseen by a board of directors with backgrounds in biotechnology, finance, and pharmaceutical development, providing oversight consistent with U.S. public company standards.